Pyrexia was the most common adverse event observed in Phase III clinical trials of Tafinlar (dabrafenib) + Mekinist (trametinib).
This brochure is designed to provide guidance on how to monitor your patients for the onset of pyrexia and advises on how best to manage pyrexia to allow continued treatment with Tafinlar + Mekinist.
Images provided for preview. Please contact your Novartis Representative to receive a copy of this brochure.